Correction: combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
Name:
Correction....pdf
Size:
378.9Kb
Format:
PDF
Description:
Found with Open Access Button
Affiliation
Faculty Institute for Cancer Sciences, University of Manchester, Manchester M13 9WL, United Kingdom.Issue Date
2024
Metadata
Show full item recordCitation
Zanjirband M, Curtin N, Edmondson RJ, Lunec J. Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer. Oncotarget. 2024 Feb 22;15:142. PubMed PMID: 38386812. Pubmed Central PMCID: PMC10883681. Epub 2024/02/22. eng.Journal
OncotargetDOI
10.18632/oncotarget.28523PubMed ID
38386812Additional Links
https://dx.doi.org/10.18632/oncotarget.28523Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.18632/oncotarget.28523
Scopus Count
Collections
Related articles
- Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.
- Authors: Zanjirband M, Curtin N, Edmondson RJ, Lunec J
- Issue date: 2017 Sep 19
- Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
- Authors: Zanjirband M, Edmondson RJ, Lunec J
- Issue date: 2016 Jun 28
- MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388).
- Authors: Khurana A, Shafer DA
- Issue date: 2019
- Co-delivery of p53 and MDM2 inhibitor RG7388 using a hydroxyl terminal PAMAM dendrimer derivative for synergistic cancer therapy.
- Authors: Chen K, Xin X, Qiu L, Li W, Guan G, Li G, Qiao M, Zhao X, Hu H, Chen D
- Issue date: 2019 Dec
- ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma.
- Authors: Wu CE, Koay TS, Esfandiari A, Ho YH, Lovat P, Lunec J
- Issue date: 2018 Dec 20